Evaluation of a rapid molecular drug-susceptibility test for tuberculosis

Yingda L. Xie, Soumitesh Chakravorty, Derek T. Armstrong, Sandra L. Hall, Laura E. Via, Taeksun Song, Xing Yuan, Xiaoying Mo, Hong Zhu, Peng Xu, Qian Gao, Myungsun Lee, Jongseok Lee, Laura E. Smith, Ray Y. Chen, Joon Sung Joh, Young Soo Cho, Xin Liu, Xianglin Ruan, Lili LiangNila Dharan, Sang Nae Cho, Clifton E. Barry, Jerrold J. Ellner, Susan E. Dorman, David Alland

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

BACKGROUND Fluoroquinolones and second-line injectable drugs are the backbone of treatment regimens for multidrug-resistant tuberculosis, and resistance to these drugs defines extensively drug-resistant tuberculosis. We assessed the accuracy of an automated, cartridge-based molecular assay for the detection, directly from sputum specimens, of Mycobacterium tuberculosis with resistance to fluoroquinolones, aminoglycosides, and isoniazid. METHODS We conducted a prospective diagnostic accuracy study to compare the investigational assay against phenotypic drug-susceptibility testing and DNA sequencing among adults in China and South Korea who had symptoms of tuberculosis. The Xpert MTB/ RIF assay and sputum culture were performed. M. tuberculosis isolates underwent phenotypic drug-susceptibility testing and DNA sequencing of the genes katG, gyrA, gyrB, and rrs and of the eis and inhA promoter regions. RESULTS Among the 308 participants who were culture-positive for M. tuberculosis, when phenotypic drug-susceptibility testing was used as the reference standard, the sensitivities of the investigational assay for detecting resistance were 83.3% for isoniazid (95% confidence interval [CI], 77.1 to 88.5), 88.4% for ofloxacin (95% CI, 80.2 to 94.1), 87.6% for moxifloxacin at a critical concentration of 0.5 μg per milliliter (95% CI, 79.0 to 93.7), 96.2% for moxifloxacin at a critical concentration of 2.0 μg per milliliter (95% CI, 87.0 to 99.5), 71.4% for kanamycin (95% CI, 56.7 to 83.4), and 70.7% for amikacin (95% CI, 54.5 to 83.9). The specificity of the assay for the detection of phenotypic resistance was 94.3% or greater for all drugs except moxifloxacin at a critical concentration of 2.0 μg per milliliter (specificity, 84.0% [95% CI, 78.9 to 88.3]). When DNA sequencing was used as the reference standard, the sensitivities of the investigational assay for detecting mutations associated with resistance were 98.1% for isoniazid (95% CI, 94.4 to 99.6), 95.8% for fluoroquinolones (95% CI, 89.6 to 98.8), 92.7% for kanamycin (95% CI, 80.1 to 98.5), and 96.8% for amikacin (95% CI, 83.3 to 99.9), and the specificity for all drugs was 99.6% (95% CI, 97.9 to 100) or greater. CONCLUSIONS This investigational assay accurately detected M. tuberculosis mutations associated with resistance to isoniazid, fluoroquinolones, and aminoglycosides and holds promise as a rapid point-of-care test to guide therapeutic decisions for patients with tuberculosis.

Original languageEnglish
Pages (from-to)1043-1054
Number of pages12
JournalNew England Journal of Medicine
Volume377
Issue number11
DOIs
Publication statusPublished - 2017 Sep 14

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Evaluation of a rapid molecular drug-susceptibility test for tuberculosis'. Together they form a unique fingerprint.

  • Cite this

    Xie, Y. L., Chakravorty, S., Armstrong, D. T., Hall, S. L., Via, L. E., Song, T., Yuan, X., Mo, X., Zhu, H., Xu, P., Gao, Q., Lee, M., Lee, J., Smith, L. E., Chen, R. Y., Joh, J. S., Cho, Y. S., Liu, X., Ruan, X., ... Alland, D. (2017). Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. New England Journal of Medicine, 377(11), 1043-1054. https://doi.org/10.1056/NEJMoa1614915